Loading
companiesCompany
Exelixis
Exelixis makes cabozantinib (Cabometyx), used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.
Overview
Exelixis, based in Alameda, California, and listed as EXEL, makes cabozantinib, sold as Cabometyx, which is used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers. Cabozantinib is approved in renal cell carcinoma alone and with nivolumab, in hepatocellular carcinoma after sorafenib on the CELESTIAL trial, in differentiated thyroid cancer, and in advanced pancreatic and extra-pancreatic neuroendocrine tumours on the CABINET trial in March 2025, and the next-generation kinase inhibitor zanzalintinib is in phase 3 in colorectal cancer and neuroendocrine tumours. OnCo also links it to adrenocortical carcinoma and osteosarcoma. Whether zanzalintinib can extend the franchise beyond cabozantinib is the open question. Cabozantinib has its own page.
Headquarters
Alameda, CA, US
Scorecard
All companies#84of 1244 companies, score 55
- approved products +6
- phase 3 +3
- targets +6
- modalities +2
- regions +6
- 24-month regulatory events +2
- registry trials +30
1 approved, 1 in phase 3, 0 earlier, 3 targets, 242 registry studies. Formula on the scorecards page.
Financial snapshot, FY2024
- Total revenue
- $2.2bn
- R&D spend
- $0.9bn
- Cash
- $1.7bn
Cabometyx and Cometriq (US) $1.8bn
Cash includes short- and long-term investments. Exelixis Form 10-K, FY2024 (SEC EDGAR)
Type
Biotech · EXEL
Stage
Public
Website
ApprovedSmall-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)
Cabozantinib · Cabometyx
A pill that blocks both blood-vessel growth and the MET escape pathway, used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.
Phase 3small molecule
Zanzalintinib is an experimental small-molecule drug from Exelixis in phase 3 trials for neuroendocrine tumours, head and neck squamous cell carcinoma and renal cell carcinoma, aimed at VEGF / VEGFR and MET.
Notes
top- Zanzalintinib (XL092) is in phase 3 across kidney cancer with belzutifan (LITESPARK-034), colorectal cancer (STELLAR-303) and neuroendocrine tumours; XB002 is the company's antibody-drug conjugate.
Similar pages
- PersonSumanta K. Pal
Shares CONTACT-03, COSMIC-313, PAPMET (SWOG S1500), Renal cell carcinoma.
- PairingCaution: PD-1 rechallenge after progression on immunotherapy (RCC)
Shares CONTACT-03, Cabozantinib, Renal cell carcinoma.
- TargetAXL
Shares Cabozantinib, Thyroid cancer, Renal cell carcinoma, Hepatocellular carcinoma.
- PersonToni K. Choueiri
Shares CheckMate 9ER, Cabozantinib, Renal cell carcinoma.
- Key paperEXAM: cabozantinib in progressive medullary thyroid cancer
Shares EXAM, Cabozantinib.
- TargetTSC2
Shares Thyroid cancer, Neuroendocrine tumours, Renal cell carcinoma, Hepatocellular carcinoma.
- Key paperPAPMET (SWOG 1500): cabozantinib versus sunitinib for metastatic papillary renal cell carcinoma
Shares PAPMET (SWOG S1500), Cabozantinib.
- TargetPRKAR1A
Shares Adrenocortical carcinoma, Thyroid cancer, Renal cell carcinoma.
cancers
fronts
drugs
ApprovedSmall-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)
Cabozantinib · Cabometyx
Phase 3small molecule
trials
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VaA Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)CABONECabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or ACabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesCELESTIALCheckMate 9ERCOMET-1CONTACT-03COSMIC-313EXAMLong-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyPan Tumor Rollover StudyPAPMET (SWOG S1500)Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCStudy of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not ReceStudy of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerStudy of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaZanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseZanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors